Advertisement
Screener

HERON THERAPEUTICS, INC. /DE/ (HRTX) Increase (Decrease) in Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

HERON THERAPEUTICS, INC. /DE/ Increase (Decrease) in Accrued Liabilities

HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Increase (Decrease) in Accrued Liabilities of -$2.01 million for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-12.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2014-05-12

  • HERON THERAPEUTICS, INC. /DE/ increase (decrease) in accrued liabilities for the quarter ending 2014-03-31 was -$2.01M, a 236.80% decline year-over-year.
  • HERON THERAPEUTICS, INC. /DE/ increase (decrease) in accrued liabilities for the quarter ending 2013-12-31 was $2.42M, a 206.46% increase year-over-year.
  • HERON THERAPEUTICS, INC. /DE/ increase (decrease) in accrued liabilities for the quarter ending 2013-09-30 was -$1.06M, a 3871.43% decline year-over-year.
  • HERON THERAPEUTICS, INC. /DE/ increase (decrease) in accrued liabilities for the quarter ending 2013-06-30 was $412.00K.
  • HERON THERAPEUTICS, INC. /DE/ increase (decrease) in accrued liabilities for fiscal 2013 was $3.24M, a 642.33% increase from fiscal 2012.
  • HERON THERAPEUTICS, INC. /DE/ increase (decrease) in accrued liabilities for fiscal 2012 was $437.00K, a 66.33% decline from fiscal 2011.
  • HERON THERAPEUTICS, INC. /DE/ increase (decrease) in accrued liabilities for fiscal 2011 was $1.30M.
  • HERON THERAPEUTICS, INC. /DE/ increase (decrease) in accrued liabilities for fiscal 2010 was -$579.00K.
Period endIncrease (Decrease) in Accrued Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities 6 monthIncrease (Decrease) in Accrued Liabilities 9 monthIncrease (Decrease) in Accrued Liabilities 12 month
2014-03-31-$2.01M
10-Q · filed 2014-05-12
$407.00K
derived: sum of 2 quarters · filed 2014-05-12
-$649.00K
derived: sum of 3 quarters · filed 2014-05-12
-$237.00K
derived: sum of 4 quarters · filed 2014-05-12
2013-12-31$2.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07
$1.36M
derived: sum of 2 quarters · filed 2014-03-07
$1.77M
derived: sum of 3 quarters · filed 2014-03-07
$3.24M
10-K · filed 2014-03-07
2013-09-30-$1.06M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
-$644.00K
derived: sum of 2 quarters · filed 2013-11-12
$826.00K
10-Q · filed 2013-11-12
$1.61M
derived: sum of 4 quarters · filed 2014-05-12
2013-06-30$412.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08
$1.88M
10-Q · filed 2013-08-08
$2.67M
derived: sum of 3 quarters · filed 2014-05-12
$2.70M
derived: sum of 4 quarters · filed 2014-05-12
2013-03-31$1.47M
10-Q · filed 2014-05-12
$2.26M
derived: sum of 2 quarters · filed 2014-05-12
$2.29M
derived: sum of 3 quarters · filed 2014-05-12
$2.21M
derived: sum of 4 quarters · filed 2014-05-12
2012-12-31$789.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07
$817.00K
derived: sum of 2 quarters · filed 2014-03-07
$741.00K
derived: sum of 3 quarters · filed 2014-03-07
$437.00K
10-K · filed 2014-03-07
2012-09-30$28.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
-$48.00K
derived: sum of 2 quarters · filed 2013-11-12
-$352.00K
10-Q · filed 2013-11-12
$236.00K
derived: sum of 4 quarters · filed 2014-03-07
2012-06-30-$76.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08
-$380.00K
10-Q · filed 2013-08-08
$208.00K
derived: sum of 3 quarters · filed 2014-03-07
$627.00K
derived: sum of 4 quarters · filed 2014-03-07
2012-03-31-$304.00K
10-Q · filed 2013-05-10
$284.00K
derived: sum of 2 quarters · filed 2014-03-07
$703.00K
derived: sum of 3 quarters · filed 2014-03-07
$1.10M
derived: sum of 4 quarters · filed 2014-03-07
2011-12-31$588.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07
$1.01M
derived: sum of 2 quarters · filed 2014-03-07
$1.40M
derived: sum of 3 quarters · filed 2014-03-07
$1.30M
10-K · filed 2014-03-07
2011-09-30$419.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05
$813.00K
derived: sum of 2 quarters · filed 2012-11-05
$710.00K
10-Q · filed 2012-11-05
$655.00K
derived: sum of 4 quarters · filed 2013-03-01
2011-06-30$394.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
$291.00K
10-Q · filed 2012-08-09
$236.00K
derived: sum of 3 quarters · filed 2013-03-01
-$1.09M
derived: sum of 4 quarters · filed 2013-03-01
2011-03-31-$103.00K
10-Q · filed 2012-05-10
-$158.00K
derived: sum of 2 quarters · filed 2013-03-01
-$1.49M
derived: sum of 3 quarters · filed 2013-03-01
2010-12-31-$55.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01
-$1.38M
derived: sum of 2 quarters · filed 2013-03-01
-$579.00K
10-K · filed 2013-03-01
2010-09-30-$1.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07
-$524.00K
10-Q · filed 2011-11-07
2010-06-30$805.00K
10-Q · filed 2011-08-08
2009-12-31-$1.16M
10-K · filed 2012-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Clene Inc. (CLNN)United States$0.054B-1.99
Serina Therapeutics, Inc. (SER)United States$0.054B-2.35
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
Xilio Therapeutics, Inc. (XLO)United States$0.052B
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
TALPHERA, INC. (TLPH)United States$0.060B
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
CalciMedica, Inc. (CALC)United States$0.061B-1.42
Lite Strategy, Inc. (LITS)United States$0.049B